high-dose chemotherapy

Phase 3Small molecule

high-dose chemotherapy is one of 101 small molecule programs targeting Primitive Neuroectodermal Tumor. It is currently in Phase 3.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primitive Neuroectodermal TumorActive, not recruiting

LymphomaActive, not recruiting

Germ Cell TumorActive, not recruiting

EnterocolitisActive, not recruiting

Recurrent Classic Hodgkin LymphomaNot yet recruiting

Primitive Neuroectodermal TumorPreclinical

Active, not recruiting

LymphomaPhase 3

Active, not recruiting

Germ Cell TumorPhase 2

Active, not recruiting

EnterocolitisPhase 1/Phase 2

Active, not recruiting

Recurrent Classic Hodgkin LymphomaPreclinical

Not yet recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

high-dose chemotherapy

EEastern Cooperative Oncology Group

Phase 3

2 2

Oncaspar

SServier

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Norvir

AbbVie

Preclinical

1 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Tafasitamab

Incyte

Preclinical

7 7

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 8

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 9

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

3 10

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Recruiting

Germ Cell Tumor

NCT06418789

PreclinicalNot yet recruiting

Recurrent Classic Hodgkin Lymphoma

NCT07572123

Q4 2033

Phase 3Not yet recruiting

Lymphoma

NCT06724237

Clinical

Trials by Indication[1]

Lymphoma2 trials

High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma

Completed·MMassachusetts General Hospital·Phase 2·NCT01182415·30 enrolled

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Not yet recruiting·EEastern Cooperative Oncology Group·Phase 3·NCT06724237·294 enrolled

Primitive Neuroectodermal Tumor1 trial

Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma

Completed·UUniversitätsklinikum Hamburg-Eppendorf·N/A·NCT00303810·567 enrolled

Enterocolitis1 trial

Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis

Unknown status·BBurnasyan Federal Medical Biophysical Center·Phase 1/2·NCT02145923·16 enrolled

Germ Cell Tumor1 trial

High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors

Recruiting·NN.N. Petrov National Medical Research Center of Oncology·Phase 2·NCT06418789·25 enrolled

Recurrent Classic Hodgkin Lymphoma1 trial

A Two Cohort Randomized Study for Patients With High Risk (Phase II) and Standard Risk (Phase III) Classical Hodgkin Lymphoma in First Relapse

Not yet recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT07572123·374 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for high-dose chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — high-dose chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for high-dose chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eastern Cooperative Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEastern Cooperative Oncology Group

high-dose chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q4 2033

Trials by Indication[1]

Lymphoma2 trials

Primitive Neuroectodermal Tumor1 trial

Enterocolitis1 trial

Germ Cell Tumor1 trial

Recurrent Classic Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News